Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Greenbaum

Showing results (11-20 of 225) with videos related to

Pageof 23
Sort By:
Diabetes|May 1, 2021
A Key to T1D Prevention: Screening and Monitoring Relatives as Part of Clinical CareCarla J Greenbaum
Journal of Clinical Engineering|April 9, 1988
Software quality assurance and system safetyJ Jorgens, J Greenbaum
Pharmacological Research|March 16, 2015
Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going?Sandra Lord, Carla J Greenbaum
The Journal of Clinical Endocrinology and Metabolism|August 8, 2007
Editorial: The role of glucagon in postprandial hyperglycemia--the jury's still outJennifer Bollyky, Carla J Greenbaum
Diabetes|May 28, 2011
Comment on: Atkinson. It's time to consider changing the rules: the rationale for rethinking control groups in clinical trials aimed at reversing type 1 diabetes. Diabetes 2011;60:361-363Srinath Sanda, Carla J Greenbaum
F1000Research|August 14, 2020
Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetesSandra Lord, Carla J Greenbaum
Nature Reviews. Endocrinology|May 18, 2023
Approval of teplizumab: implications for patientsCate Speake, Carla J Greenbaum
Diabetes|April 30, 2003
Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetesCarla J Greenbaum, Leonard C Harrison,
Diabetes|May 25, 2013
Response to Comment on: Greenbaum et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite type 1 diabetes TrialNet data. Diabetes 2012;61:2066-2073Carla J Greenbaum, Craig A Beam,
Diabetic Medicine : a Journal of the British Diabetic Association|February 1, 1991
Insulin antibodies and insulin autoantibodiesC J Greenbaum, J P Palmer
Pageof 23

Showing results (11-20 of 225) with videos related to

Sort By:
Pageof 23
Diabetes|May 1, 2021
A Key to T1D Prevention: Screening and Monitoring Relatives as Part of Clinical CareCarla J Greenbaum
Journal of Clinical Engineering|April 9, 1988
Software quality assurance and system safetyJ Jorgens, J Greenbaum
Pharmacological Research|March 16, 2015
Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going?Sandra Lord, Carla J Greenbaum
The Journal of Clinical Endocrinology and Metabolism|August 8, 2007
Editorial: The role of glucagon in postprandial hyperglycemia--the jury's still outJennifer Bollyky, Carla J Greenbaum
Diabetes|May 28, 2011
Comment on: Atkinson. It's time to consider changing the rules: the rationale for rethinking control groups in clinical trials aimed at reversing type 1 diabetes. Diabetes 2011;60:361-363Srinath Sanda, Carla J Greenbaum
F1000Research|August 14, 2020
Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetesSandra Lord, Carla J Greenbaum
Nature Reviews. Endocrinology|May 18, 2023
Approval of teplizumab: implications for patientsCate Speake, Carla J Greenbaum
Diabetes|April 30, 2003
Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetesCarla J Greenbaum, Leonard C Harrison,
Diabetes|May 25, 2013
Response to Comment on: Greenbaum et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite type 1 diabetes TrialNet data. Diabetes 2012;61:2066-2073Carla J Greenbaum, Craig A Beam,
Diabetic Medicine : a Journal of the British Diabetic Association|February 1, 1991
Insulin antibodies and insulin autoantibodiesC J Greenbaum, J P Palmer
Pageof 23